
|Articles|September 1, 2006
- ONCOLOGY Vol 20 No 10
- Volume 20
- Issue 10
Wall Chart Featuring Skin-Related Toxicities of Targeted Therapies
Wall Chart Featuring Skin-Related Toxicities of Targeted Therapies
Advertisement
Download the wall chart of Skin-Related Toxicities of Targeted Therapies as a PDF.
Articles in this issue
over 19 years ago
Complete Guide to Colorectal Cancerover 19 years ago
Decitabine Receives US Orphan Drug Designation for AMLover 19 years ago
New Questions About Transplantation in Multiple Myeloma: Review 1over 19 years ago
FDA Approves Drug Combination for Ovarian Cancer Recurrenceover 19 years ago
Stage III Lung Cancer: Two or Three Modalities? Review 1Advertisement
Related Content
Advertisement

ByPatrick Neven, MD, PhD,Andre Mattar,Antonio Llombart-Cussac,Giuseppe Curigliano,Nadia Harbeck, MD, PhD,Joyce O’Shaughnessy, MD,François-Clément Bidard,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Cristina Saura,Lisa A. Carey, MD,Kamnesh R. Pradhan,Shanshan Cao,Monique Coersmeyer,Anna Emde,Francisco Sapunar,Komal L. Jhaveri,Philippe Aftimos




93 monarchE: Primary Overall Survival Results of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer
ByStephen R.D. Johnston,Miguel Martin, MD, PhD,Joyce O’Shaughnessy, MD,Roberto Hegg,Sara M. Tolaney, MD, MPH,Valentina Guarneri, MD,Lucia Del Mastro,Mario Campone,Javier Cortés, MD,Hope S. Rugo, MD,Matthew P. Goetz, MD,Erika P. Hamilton, MD,Elzbieta Senkus,Laura Testa,Patrick Neven, MD, PhD,Jens Huober, MD,Ran Wei,Maria Munoz,Priya Rastogi, MD,Nadia Harbeck, MD, PhD,Victoria Jennifer Stefaniak (Non-Author Presenter)
Advertisement
Advertisement
Trending on CancerNetwork
1
Concomitant COVID-19 Vaccination Tied to Improved OS With Immunotherapy
2
Anticipated Data and Practice-Changing Trials: An ASCO 2026 Breast Cancer Preview
3
FDA Approves FoundationOne CDx for Tepotinib in MET+ NSCLC
4
Navigating CAR T-Cell Therapy Use as a “Team Sport” in Multiple Myeloma
5
























































